Latest General Interest Stories

Biosimilars: Providing More Treatment Options
ArticlesDrug Discovery and DevelopmentGeneral Interest

Biosimilars: Providing More Treatment Options

It is hoped that the development of biosimilars will lead to more accessible and cost-effective treatment options. Here we explore the current opportunities for biosimilars in rheumatoid arthritis and discuss the opportunities and concerns tied to their use.
READ MORE →
What's New in U.S. Biosimilar-Land?
ArticlesDrug Discovery and DevelopmentFeatured StoriesGeneral Interest

What’s New in U.S. Biosimilar-Land?

Biosimilars are gaining in popularity and estimates predict that the U.S. could save between $40–250 billion in healthcare costs over the next decade by switching from biologics to biosimilars. See how biosimilars have gained in popularity recently, the challenges the U.S. faces in developing them, and what the future holds.
READ MORE →

More General Interest Stories